These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J; Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182 [TBL] [Abstract][Full Text] [Related]
5. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Tehfe M; Dowden S; Kennecke H; El-Maraghi R; Lesperance B; Couture F; Letourneau R; Liu H; Romano A Adv Ther; 2016 May; 33(5):747-59. PubMed ID: 27085323 [TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697 [TBL] [Abstract][Full Text] [Related]
7. First-line treatment for advanced pancreatic cancer. Kothari N; Saif MW; Kim R JOP; 2013 Mar; 14(2):129-32. PubMed ID: 23474553 [TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic pancreatic adenocarcinoma: a review. Thota R; Pauff JM; Berlin JD Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517 [TBL] [Abstract][Full Text] [Related]
10. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490 [TBL] [Abstract][Full Text] [Related]
11. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248 [TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079 [TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
14. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. Saif MW JOP; 2013 Nov; 14(6):686-8. PubMed ID: 24216565 [No Abstract] [Full Text] [Related]
15. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943 [TBL] [Abstract][Full Text] [Related]
16. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study. Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903 [TBL] [Abstract][Full Text] [Related]
18. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G Digestion; 2016; 94(4):222-229. PubMed ID: 28030863 [TBL] [Abstract][Full Text] [Related]
19. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. Blomstrand H; Scheibling U; Bratthäll C; Green H; Elander NO BMC Cancer; 2019 Jan; 19(1):40. PubMed ID: 30621618 [TBL] [Abstract][Full Text] [Related]
20. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Sonbol MB; Ahn DH; Goldstein D; Okusaka T; Tabernero J; Macarulla T; Reni M; Li CP; O'Neil B; Van Cutsem E; Bekaii-Saab T Future Oncol; 2019 Apr; 15(12):1295-1302. PubMed ID: 30768369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]